TY - JOUR
T1 - Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder
AU - Revicki, Dennis A.
AU - Althof, Stanley E.
AU - Derogatis, Leonard R.
AU - Kingsberg, Sheryl A.
AU - Wilson, Hilary
AU - Sadiq, Amama
AU - Krop, Julie
AU - Jordan, Robert
AU - Lucas, Johna
N1 - Funding Information:
The authors wish to thank all participants in these studies, their families, and the personnel at all study sites. The authors were responsible for all content and editorial decisions, and received no honoraria related to the development of this manuscript. Editorial support in the preparation of this manuscript was provided by Phase Five Communications, funded by AMAG Pharmaceuticals, Inc., the licensee of bremelanotide.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Background: The Elements of Desire Questionnaire (EDQ) is a patient-reported outcome (PRO) measure developed to evaluate sexual desire and was included in two identically designed phase 3 clinical trials (RECONNECT) as an exploratory endpoint. The EDQ was developed based on a literature review, qualitative research with patients with hypoactive sexual desire disorder (HSDD), and input from clinical experts. This instrument is intended to be used to collect efficacy data in clinical trials evaluating potential treatments for HSDD. The objective of this study was to evaluate the measurement properties of both the monthly and daily recall versions of the EDQ during the RECONNECT trials. Methods: Participants completed the EDQ daily version for 7 consecutive days prior to selected monthly clinic visits. The monthly recall version was completed at each monthly clinic visit. The analysis population consisted of all subjects with Female Sexual Function Index (FSFI) data at baseline and ≥ 1 follow-up visit. Results: At baseline, 1144 and 676 subjects completed the monthly and daily recall EDQs, respectively. The EDQ scores had good internal consistency and test-retest reliability. Monthly and daily recall EDQ scores were correlated with FSFI-desire domain scores at baseline and month 3. Scores from the monthly and daily recall versions were also correlated. After 6 months, there was a significantly greater improvement for bremelanotide versus placebo in both the monthly and daily recall versions (both P < 0.0001). Conclusions: The results demonstrated that EDQ exhibited good reliability, validity, and sensitivity to change. Consistent with other validated PRO measures of sexual desire, the EDQ provides additional insights into sexual desire. Trial registration: NCT02338960 and NCT02333071 (RECONNECT studies).
AB - Background: The Elements of Desire Questionnaire (EDQ) is a patient-reported outcome (PRO) measure developed to evaluate sexual desire and was included in two identically designed phase 3 clinical trials (RECONNECT) as an exploratory endpoint. The EDQ was developed based on a literature review, qualitative research with patients with hypoactive sexual desire disorder (HSDD), and input from clinical experts. This instrument is intended to be used to collect efficacy data in clinical trials evaluating potential treatments for HSDD. The objective of this study was to evaluate the measurement properties of both the monthly and daily recall versions of the EDQ during the RECONNECT trials. Methods: Participants completed the EDQ daily version for 7 consecutive days prior to selected monthly clinic visits. The monthly recall version was completed at each monthly clinic visit. The analysis population consisted of all subjects with Female Sexual Function Index (FSFI) data at baseline and ≥ 1 follow-up visit. Results: At baseline, 1144 and 676 subjects completed the monthly and daily recall EDQs, respectively. The EDQ scores had good internal consistency and test-retest reliability. Monthly and daily recall EDQ scores were correlated with FSFI-desire domain scores at baseline and month 3. Scores from the monthly and daily recall versions were also correlated. After 6 months, there was a significantly greater improvement for bremelanotide versus placebo in both the monthly and daily recall versions (both P < 0.0001). Conclusions: The results demonstrated that EDQ exhibited good reliability, validity, and sensitivity to change. Consistent with other validated PRO measures of sexual desire, the EDQ provides additional insights into sexual desire. Trial registration: NCT02338960 and NCT02333071 (RECONNECT studies).
KW - Bremelanotide
KW - Female sexual dysfunction
KW - Hypoactive sexual desire disorder
KW - Patient-reported outcomes
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=85092323469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092323469&partnerID=8YFLogxK
U2 - 10.1186/s41687-020-00241-6
DO - 10.1186/s41687-020-00241-6
M3 - Article
C2 - 33033885
AN - SCOPUS:85092323469
SN - 2509-8020
VL - 4
JO - Journal of Patient-Reported Outcomes
JF - Journal of Patient-Reported Outcomes
IS - 1
M1 - 82
ER -